April Journal-2009.p65 - Association of Biotechnology and Pharmacy

Current Trends in Biotechnology and Pharmacy
Vol. 3 (2) 149-154, April 2009. ISSN 0973-8916
protease inhibitors (4,5) and HIV-1 integrase
inhibitors (6,7) and gp 120 envelope glycoprotein
(8) were reported. Leonard et al. has developed
a few QSAR models for anti-HIV activities of
different group of compounds (9,10). The present
group of authors has developed a few quantitative
structure-activity relationship models to predict
anti-HIV activity of different group of compounds
(11-20). In continuation of such efforts, in this
article, we have performed QSAR analysis to
explore the correlation between physicochemical
and biological activity of thiomethane derivatives
using modeling software WIN CAChe 6.1
(molecular modeling software, a product of Fujitsu
private limited, Japan) and statistical software
STATISTICA version 6 (StatSoft, Inc., Tulsa,
USA).
Materials and Methods
In the present work we have taken 16
thiomethane compounds (Table 1) and their HIV-
1 protease inhibitory activity from the reported
work (21). Many of these compounds inhibited
wild type HIV-1 protease with IC 50
values
between 0.058 μM and 7.82 μM. There is high
structural diversity and a sufficient range of the
biological activity in the selected series of
thiomethane derivatives. It insists as to select these
series of compounds for our QSAR studies. All
the HIV-1 protease inhibitory activities used in
the present study were expressed as pIC 50
= -
log 10
IC 50
. Where IC 50
is the micro molar
concentration of the compounds producing 50%
reduction in the HIV-1 protease activity is stated
as the means of at least two experiments. The
compounds which did not show confirmed HIV-
1 protease inhibitory activity and the compounds
having particular functional groups at a particular
position once in the above cited literature have
not been taken for our study. We carried out
QSAR analysis and established a QSAR model
to guide further structural optimization and predict
the potency and physiochemical properties of
clinical drug candidates.
150
All the sixteen compounds (13
compounds in training set and three in test set,
training and test set selection has been done
manually) were built on workspace of molecular
modeling software WIN CAChe 6.1, which is a
product of Fujitsu private limited, Japan. The
energy minimization was done by geometry
optimization of molecules using MM2 (Molecular
Mechanics) followed by semi empirical PM3
method available in MOPAC module until the root
mean square gradient value becomes smaller than
0.001 kcal/mol Å. The physicochemical properties
were calculated on project leader file of the
software. These properties were fed manually
into statistical software named STATISTICA
version 6 (StatSoft, Inc., Tulsa, USA) and a
correlation matrix was made to select the
parameters having very less inter-correlation and
maximum correlation with activity. This was
followed by multiple linear regression analysis to
achieve best model.
Internal validation was carried out by
Leave one out (LOO) method using statistical
software STATISTICA. The cross-validated
correlation coefficient, q 2 , was calculated using
the following equation:
q 2 = 1 – PRESS / ∑ (y i
- y m
) 2
N
N
i=1
PRESS = ∑ (y pred,i
– y i
) 2
i=1
Where y i
is the activity for training set
compounds, y m
is the mean observed value,
corresponding to the mean of the values for each
cross-validation group, and y pred,i
is the predicted
activity for y i
. The LOO predicted values are
shown in table 1.
In present study the calculated
descriptors were conformational minimum
energies (CME), Zero-order connectivity index
Ravichandran et al